

Novel therapeutic targets on the horizon for lung cancer

Lancet Oncology, The
17, e347-e362

DOI: 10.1016/s1470-2045(16)30123-1

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Emerging therapeutic agents for lung cancer. Journal of Hematology and Oncology, 2016, 9, 138. | 17.0 | 77 |
| 2 | Graphene Oxide Induced Perturbation to Plasma Membrane and Cytoskeletal Meshwork Sensitize Cancer Cells to Chemotherapeutic Agents. ACS Nano, 2017, 11, 2637-2651. | 14.6 | 110 |
| 3 | Sample types applied for molecular diagnosis of therapeutic management of advanced non-small cell lung cancer in the precision medicine. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1817-1833. | 2.3 | 13 |
| 4 | Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway. Lung Cancer, 2017, 106, 115-124. | 2.0 | 22 |
| 5 | CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer. Lung Cancer, 2017, 113, 121-127. | 2.0 | 14 |
| 6 | Src-dependent EGFR transactivation regulates lung inflammation via downstream signaling involving ERK1/2, PI3K/Akt and NF- κ B induction in a murine asthma model. Scientific Reports, 2017, 7, 9919. | 3.3 | 55 |
| 7 | On the "TRAIL" of a Killer: MMP12 in Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 262-264. | 5.6 | 5 |
| 8 | Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1679-1686. | 1.1 | 30 |
| 9 | Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers. Scientific Reports, 2017, 7, 17530. | 3.3 | 53 |
| 10 | Exhaustive preoperative staging increases survival in resected adrenal oligometastatic non-small-cell lung cancer: a multicentre study. European Journal of Cardio-thoracic Surgery, 2017, 52, 698-703. | 1.4 | 14 |
| 11 | ZAR1 is a novel epigenetically inactivated tumour suppressor in lung cancer. Clinical Epigenetics, 2017, 9, 60. | 4.1 | 15 |
| 12 | Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art. European Journal of Radiology, 2017, 86, 297-307. | 2.6 | 222 |
| 13 | Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. Theranostics, 2017, 7, 4753-4762. | 10.0 | 25 |
| 14 | Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer. Oncotarget, 2017, 8, 103055-103062. | 1.8 | 47 |
| 15 | The Role of IL-33-Dependent Inflammation in the Tumor Microenvironment. Frontiers in Immunology, 2016, 7, 682. | 4.8 | 64 |
| 16 | Gold nanoparticles enhance TRAIL sensitivity through Drp1-mediated apoptotic and autophagic mitochondrial fission in NSCLC cells. International Journal of Nanomedicine, 2017, Volume 12, 2531-2551. | 6.7 | 66 |
| 17 | PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. Journal of Thoracic Disease, 2017, 9, E384-E386. | 1.4 | 17 |
| 18 | Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 12-17. | 3.8 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade. <i>Journal of Clinical Oncology</i> , 2017, 35, 2735-2736. | 1.6 | 4 |
| 20 | Predictive factors for treatment response using dual-energy computed tomography in patients with advanced lung adenocarcinoma. <i>European Journal of Radiology</i> , 2018, 101, 118-123. | 2.6 | 17 |
| 21 | A strategy to analyse activity-based profiling of tyrosine kinase substrates in OCT-embedded lung cancer tissue. <i>Analytical Biochemistry</i> , 2018, 547, 77-83. | 2.4 | 1 |
| 22 | KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e489-e501. | 2.6 | 32 |
| 23 | Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3073-3085. | 3.6 | 23 |
| 24 | Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology. <i>Cancer Investigation</i> , 2018, 36, 37-58. | 1.3 | 15 |
| 25 | Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774501. | 3.2 | 101 |
| 26 | ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway. <i>Oncology Reports</i> , 2018, 39, 2892-2898. | 2.6 | 32 |
| 27 | Acetyl-macrocalin B, an ent-kaurane diterpenoid, initiates apoptosis through the ROS-p38-caspase 9-dependent pathway and induces G2/M phase arrest via the Chk1/2-Cdc25C-Cdc2/cyclin B axis in non-small cell lung cancer. <i>Cancer Biology and Therapy</i> , 2018, 19, 609-621. | 3.4 | 16 |
| 28 | Results of the first external quality assessment scheme (EQA) for isolation and analysis of circulating tumour DNA (ctDNA). <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 220-228. | 2.3 | 59 |
| 29 | TGF β 2 pathway inhibition in the treatment of non-small cell lung cancer. , 2018, 184, 112-130. | | 85 |
| 30 | Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S13-S18. | 2.8 | 1 |
| 31 | Regulation Mechanism of MicroRNAs in Non-Small Cell Lung Cancer. <i>Current Pharmaceutical Design</i> , 2018, 23, 5973-5982. | 1.9 | 5 |
| 32 | Development of dual-drug-loaded stealth nanocarriers for targeted and synergistic anti-lung cancer efficacy. <i>Drug Delivery</i> , 2018, 25, 1932-1942. | 5.7 | 34 |
| 33 | Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 5178-5183. | 1.4 | 2 |
| 34 | Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy. <i>Cancer Cytopathology</i> , 2018, 126, 860-871. | 2.4 | 11 |
| 35 | Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. <i>Oncotarget</i> , 2018, 9, 26226-26242. | 1.8 | 14 |
| 36 | Elevated expression of podoplanin and its clinicopathological, prognostic, and therapeutic values in squamous non-small cell lung cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 1329-1340. | 1.9 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. <i>Oncotarget</i> , 2018, 9, 11805-11815. | 1.8 | 9 |
| 38 | Design, synthesis, and evaluation of chalcone analogues incorporate α,β -Unsaturated ketone functionality as anti-lung cancer agents via evoking ROS to induce pyroptosis. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 1395-1405. | 5.5 | 47 |
| 39 | Establishment of lung cancer patient-derived xenograft models and primary cell lines for lung cancer study. <i>Journal of Translational Medicine</i> , 2018, 16, 138. | 4.4 | 16 |
| 40 | Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. <i>Oncotarget</i> , 2018, 9, 20134-20155. | 1.8 | 46 |
| 41 | SNCA Is a Functionally Low-Expressed Gene in Lung Adenocarcinoma. <i>Genes</i> , 2018, 9, 16. | 2.4 | 44 |
| 42 | MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 195. | 8.6 | 20 |
| 43 | Chemotherapy of malignancy. , 2018, , 631-656. | | 1 |
| 44 | Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). <i>International Journal of Molecular Sciences</i> , 2019, 20, 3821. | 4.1 | 116 |
| 45 | ILF2 promotes anchorage independence through direct regulation of PTEN. <i>Oncology Letters</i> , 2019, 18, 1689-1696. | 1.8 | 6 |
| 46 | <p>Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7707-7719. | 1.9 | 45 |
| 47 | Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Nonâ€Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e196879. | 5.9 | 161 |
| 48 | TFAP2A Induced KRT16 as an Oncogene in Lung Adenocarcinoma via EMT. <i>International Journal of Biological Sciences</i> , 2019, 15, 1419-1428. | 6.4 | 44 |
| 49 | Exploiting ING2 Epigenetic Modulation as a Therapeutic Opportunity for Non-Small Cell Lung Cancer. <i>Cancers</i> , 2019, 11, 1601. | 3.7 | 8 |
| 50 | Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas. <i>Theranostics</i> , 2019, 9, 7122-7139. | 10.0 | 38 |
| 51 | Ang-(1-7)/ MAS1 receptor axis inhibits allergic airway inflammation via blockade of Src-mediated EGFR transactivation in a murine model of asthma. <i>PLoS ONE</i> , 2019, 14, e0224163. | 2.5 | 16 |
| 52 | ADAM17: An Emerging Therapeutic Target for Lung Cancer. <i>Cancers</i> , 2019, 11, 1218. | 3.7 | 57 |
| 53 | Transfer of Extracellular Vesicle-Associated-RNAs Induces Drug Resistance in ALK-Translocated Lung Adenocarcinoma. <i>Cancers</i> , 2019, 11, 104. | 3.7 | 22 |
| 54 | <p>Abietic acid suppresses non-small-cell lung cancer cell growth via blocking $IKK\beta/NF-\kappa B$ signaling</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4825-4837. | 2.0 | 36 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Cucurbitacin E inhibits the Yes-associated protein signaling pathway and suppresses brain metastasis of human non-small cell lung cancer in a murine model. <i>Oncology Reports</i> , 2019, 42, 697-707. | 2.6 | 19 |
| 56 | Methionine is a metabolic dependency of tumor-initiating cells. <i>Nature Medicine</i> , 2019, 25, 825-837. | 30.7 | 226 |
| 57 | Schizandrin A enhances the efficacy of gefitinib by suppressing IKK β /NF- κ B signaling in non-small cell lung cancer. <i>European Journal of Pharmacology</i> , 2019, 855, 10-19. | 3.5 | 21 |
| 58 | Treatment According to Molecular Profiling in Relapsed/Refractory Cancer Patients: A Review Focusing on Latest Profiling Studies. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 447-453. | 4.1 | 17 |
| 59 | miR-497-5p inhibits tumor cell growth and invasion by targeting SOX5 in non-small cell lung cancer. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 10587-10595. | 2.6 | 47 |
| 60 | Efficacy of carboplatin plus S-1 for the treatment of non-small cell lung cancer. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT 0 Overloc</i> | 1.0 | 10 |
| 61 | Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer. , 2019, 194, 59-72. | | 45 |
| 62 | Identification of a metastatic lung adenocarcinoma of the palate mucosa through genetic and histopathological analysis: a rare case report and literature review. <i>BMC Cancer</i> , 2019, 19, 52. | 2.6 | 5 |
| 63 | Interleukin-33 and ST2 Signaling in Tumor Microenvironment. <i>Journal of Interferon and Cytokine Research</i> , 2019, 39, 61-71. | 1.2 | 29 |
| 64 | Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer. <i>Journal of Cancer Education</i> , 2020, 35, 345-351. | 1.3 | 3 |
| 65 | The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis. <i>Carcinogenesis</i> , 2020, 41, 527-538. | 2.8 | 24 |
| 66 | Knockdown of lncRNA ZFAS1 suppressed non-small cell lung cancer progression via targeting the miR-150/HMGA2 signaling. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3814-3824. | 2.6 | 26 |
| 67 | Systematic evaluation of PAXgene \textregistered tissue fixation for the histopathological and molecular study of lung cancer. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 40-54. | 3.0 | 8 |
| 68 | Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 372-390. | 5.4 | 19 |
| 69 | Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma. <i>Thoracic Cancer</i> , 2020, 11, 346-352. | 1.9 | 13 |
| 70 | <p>The Effect and Safety of Anti-PD-1 Single/Combination Therapy in Refractory Thymic Carcinoma: A Case-Series Study</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 11351-11358. | 1.9 | 3 |
| 71 | BMI1-Mediated Pemetrexed Resistance in Non-Small Cell Lung Cancer Cells Is Associated with Increased SP1 Activation and Cancer Stemness. <i>Cancers</i> , 2020, 12, 2069. | 3.7 | 20 |
| 72 | Combined Treatment of Non-Small-Cell Lung Cancer Using Shenyi Capsule and Platinum-Based Chemotherapy: A Meta-Analysis and Systematic Review. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-12. | 1.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | <p>Puerarin Enhances the Anti-Tumor Effect of Cisplatin on Drug-Resistant A549 Cancer in vivo and in vitro Through Activation of the Wnt Signaling Pathway</p>. Cancer Management and Research, 2020, Volume 12, 6279-6289. | 1.9 | 6 |
| 74 | Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469. | | 59 |
| 75 | PNO1, which is negatively regulated by miR-340-5p, promotes lung adenocarcinoma progression through Notch signaling pathway. Oncogenesis, 2020, 9, 58. | 4.9 | 20 |
| 76 | The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC). Cancers, 2020, 12, 1361. | 3.7 | 39 |
| 77 | RNF115-mediated ubiquitination of p53 regulates lung adenocarcinoma proliferation. Biochemical and Biophysical Research Communications, 2020, 530, 425-431. | 2.1 | 14 |
| 78 | Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors. Frontiers in Immunology, 2020, 11, 1173. | 4.8 | 26 |
| 79 | Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study. Lancet Oncology, The, 2020, 21, 723-732. | 10.7 | 22 |
| 80 | Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients â€“ A systematic review. Critical Reviews in Oncology/Hematology, 2020, 153, 103035. | 4.4 | 5 |
| 81 | Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer, 2020, 147, 83-90. | 2.0 | 12 |
| 82 | High ubiquitin conjugating enzyme E2 T mRNA expression and its prognostic significance in lung adenocarcinoma. Medicine (United States), 2020, 99, e18543. | 1.0 | 7 |
| 83 | SOX2â€“induced upregulation of lncRNA LINC01561 promotes nonâ€“smallâ€“cell lung carcinoma progression by sponging miRâ€“760 to modulate SHCBP1 expression. Journal of Cellular Physiology, 2020, 235, 6684-6696. | 4.1 | 17 |
| 84 | High GJB2 mRNA expression and its prognostic significance in lung adenocarcinoma: a study based on the TCGA database. Medicine (United States), 2020, 99, e19054. | 1.0 | 8 |
| 85 | <p>Rationale for Lung Adenocarcinoma Prevention and Drug Development Based on Molecular Biology During Carcinogenesis</p>. OncoTargets and Therapy, 2020, Volume 13, 3085-3091. | 2.0 | 25 |
| 86 | HSP70 regulates cell proliferation and apoptosis in actinomycin-D-treated lung cancer cells. Translational Cancer Research, 2020, 9, 1167-1173. | 1.0 | 1 |
| 87 | MIR-301b-3p Promotes Lung Adenocarcinoma Cell Proliferation, Migration and Invasion by Targeting DLC1. Technology in Cancer Research and Treatment, 2021, 20, 153303382199003. | 1.9 | 11 |
| 88 | Deciphering the T790M/L858R-Selective Inhibition Mechanism of an Allosteric Inhibitor of EGFR: Insights from Molecular Simulations. ACS Chemical Neuroscience, 2021, 12, 462-472. | 3.5 | 7 |
| 89 | Pan-cancer investigation reveals mechanistic insights of planar cell polarity gene Fuz in carcinogenesis. Aging, 2021, 13, 7259-7283. | 3.1 | 10 |
| 90 | COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis. Frontiers in Pharmacology, 2021, 12, 619732. | 3.5 | 13 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | The long non-coding RNA SNHG4/microRNA-let-7e/KDM3A/p21 pathway is involved in the development of non-small cell lung cancer. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 634-645. | 4.4 | 20 |
| 92 | <scp>LncRNA FAM83A</scp> promotes <scp>lung adenocarcinoma</scp> progression by enhancing the <scp>pre-mRNA</scp> stability of <scp>FAM83A</scp>. <i>Thoracic Cancer</i> , 2021, 12, 1495-1502. | 1.9 | 18 |
| 93 | Population-level changes in outcomes and Medicare cost following the introduction of new cancer therapies. <i>Health Services Research</i> , 2021, 56, 486-496. | 2.0 | 3 |
| 94 | Erlotinib Activates Different Cell Death Pathways in EGFR-mutant Lung Cancer Cells Grown in 3D <i>Versus</i> 2D Culture Systems. <i>Anticancer Research</i> , 2021, 41, 1261-1269. | 1.1 | 5 |
| 95 | Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer. <i>Cancers</i> , 2021, 13, 1316. | 3.7 | 5 |
| 96 | Body composition as a modulator of response to immunotherapy in lung cancer: time to deal with it. <i>ESMO Open</i> , 2021, 6, 100095. | 4.5 | 8 |
| 97 | Role of H2B mono-ubiquitination in the initiation and progression of cancer. <i>Bulletin Du Cancer</i> , 2021, 108, 385-398. | 1.6 | 10 |
| 98 | MCTS1 promotes the development of lung adenocarcinoma by regulating E2F1 expression. <i>Oncology Letters</i> , 2021, 22, 531. | 1.8 | 5 |
| 99 | cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 6125-6136. | 3.6 | 3 |
| 101 | Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy. <i>BMC Cancer</i> , 2021, 21, 752. | 2.6 | 11 |
| 102 | The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database. <i>BMC Cancer</i> , 2021, 21, 825. | 2.6 | 22 |
| 103 | Tumorigenic effect of <i>TERT</i> and its potential therapeutic target in NSCLC (Review). <i>Oncology Reports</i> , 2021, 46, . | 2.6 | 10 |
| 105 | Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges. <i>Cancer Treatment Reviews</i> , 2021, 99, 102250. | 7.7 | 6 |
| 106 | Overexpression of Teashirt Homolog 2 suppresses cell proliferation and predicts the favorable survival of Lung Adenocarcinoma. <i>International Journal of Medical Sciences</i> , 2021, 18, 1980-1989. | 2.5 | 2 |
| 107 | Phosphoproteomics Profiling to Identify Altered Signaling Pathways and Kinase-Targeted Cancer Therapies. <i>Methods in Molecular Biology</i> , 2020, 2051, 241-264. | 0.9 | 3 |
| 108 | Precision Medicine in Lung Cancer. <i>Molecular Pathology Library</i> , 2018, , 3-13. | 0.1 | 1 |
| 109 | Genomic landscape of lung adenocarcinoma in East Asians. <i>Nature Genetics</i> , 2020, 52, 177-186. | 21.4 | 281 |
| 110 | Gene-gene and gene-environment interaction data for platinum-based chemotherapy in non-small cell lung cancer. <i>Scientific Data</i> , 2018, 5, 180284. | 5.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 112 | Establishment and Characterization of Pemetrexed-resistant NCI-H460/PMT Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 731-739. | 1.7 | 5 |
| 114 | TMEM16A, a Homoharringtonine Receptor, as a Potential Endogenic Target for Lung Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10930. | 4.1 | 16 |
| 115 | Role of downregulated ADARB1 in lung squamous cell carcinoma. <i>Molecular Medicine Reports</i> , 2020, 21, 1517-1526. | 2.4 | 4 |
| 117 | Expression profile and prognostic values of STAT family members in non-small cell lung cancer. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 4866-4880. | 0.0 | 14 |
| 121 | Targeting Mitochondria as a Novel Disease-Modifying Therapeutic Strategy in Cancer. , 2022, , 241-262. | | 0 |
| 122 | Evolution of small cell lung cancer tumor mutation: from molecular mechanisms to novel viewpoints. <i>Seminars in Cancer Biology</i> , 2022, 86, 346-355. | 9.6 | 4 |
| 123 | TRIM46 activates AKT/HK2 signaling by modifying PHLP2 ubiquitylation to promote glycolysis and chemoresistance of lung cancer cells. <i>Cell Death and Disease</i> , 2022, 13, 285. | 6.3 | 21 |
| 124 | Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials. <i>Lung Cancer</i> , 2022, 167, 65-72. | 2.0 | 6 |
| 125 | DNA methylation molecular subtypes for prognosis prediction in lung adenocarcinoma. <i>BMC Pulmonary Medicine</i> , 2022, 22, 133. | 2.0 | 4 |
| 126 | Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. <i>BMC Cancer</i> , 2021, 21, 1322. | 2.6 | 7 |
| 127 | LncRNA MAGI2-AS3 acts as a tumor suppressor that attenuates non-small cell lung cancer progression by targeting the miR-629-5p/TXNIP axis. <i>Annals of Translational Medicine</i> , 2021, 9, 1793-1793. | 1.7 | 7 |
| 128 | Current Research Progress of the Role of LncRNA LEF1-AS1 in a Variety of Tumors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 750084. | 3.7 | 3 |
| 132 | Discoidin domain receptor 1 promotes lung adenocarcinoma migration via the AKT/snail signaling axis. <i>Molecular Biology Reports</i> , 2022, 49, 7275-7286. | 2.3 | 5 |
| 133 | Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 172. | 8.6 | 2 |
| 135 | A Machine Learning and Radiomics Approach in Lung Cancer for Predicting Histological Subtype. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 5829. | 2.5 | 6 |
| 136 | Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. <i>Frontiers in Pharmacology</i> , 0, 13, . | 3.5 | 4 |
| 138 | Clinical significance of STING expression and methylation in lung adenocarcinoma based on bioinformatics analysis. <i>Scientific Reports</i> , 2022, 12, . | 3.3 | 2 |
| 139 | Targeting Tumors Through Enhancers of Oxidative Stress. , 2022, , 3629-3648. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 140 | Exosomeâ€delivered <scp>circSATB2</scp> targets the <scp>miR</scp> â€330â€5p/ <scp>PEAK1</scp> axis to regulate proliferation, migration and invasion of lung cancer cells. Thoracic Cancer, 0, , . | 1.9 | 2 |
| 141 | G protein subunit gamma 5 promotes the proliferation, metastasis and glycolysis of breast cancer cells through the Wnt/Î²-catenin pathway. Anti-Cancer Drugs, 2022, 33, 1004-1011. | 1.4 | 0 |
| 142 | Comprehensive analyses of one-carbon metabolism related genes and their association with prognosis, tumor microenvironment, chemotherapy resistance and immunotherapy in lung adenocarcinoma. Frontiers in Molecular Biosciences, 0, 9, . | 3.5 | 2 |
| 143 | The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy. Seminars in Cancer Biology, 2022, 87, 160-169. | 9.6 | 15 |
| 144 | Retinoblastoma Expression and Targeting by CDK4/6 Inhibitors in Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2023, 22, 264-273. | 4.1 | 3 |
| 145 | Mutation patterns and evolutionary action score of <scp><i>TP53</i></scp> enable identification of a patient population with poor prognosis in advanced nonâ€small cell lung cancer. Cancer Medicine, 2023, 12, 6649-6658. | 2.8 | 2 |
| 146 | Inâ€depth proteomics reveals the characteristic developmental profiles of early lung adenocarcinoma with epidermal growth factor receptor mutation. Cancer Medicine, 0, , . | 2.8 | 1 |
| 147 | Labyrinthin Expression Is Associated with Poor Prognosis in Patients with Non-Small-Cell Lung Cancer. Cancers, 2023, 15, 924. | 3.7 | 1 |
| 148 | An artificial intelligence networkâ€guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms. Cell Proliferation, 2023, 56, . | 5.3 | 10 |
| 149 | Targeting the KRT16-vimentin axis for metastasis in lung cancer. Pharmacological Research, 2023, 193, 106818. | 7.1 | 1 |
| 150 | Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer. Cancer Treatment and Research Communications, 2023, 36, 100730. | 1.7 | 1 |
| 151 | UPF1 regulates FOXO1 protein expression by promoting PBK transcription in non-small cell lung cancer. Biochemical and Biophysical Research Communications, 2023, 666, 10-20. | 2.1 | 2 |
| 152 | Radiogenomics: a key component of precision cancer medicine. British Journal of Cancer, 2023, 129, 741-753. | 6.4 | 4 |
| 153 | E3 ligase SOCS3 regulates NOD2 expression by ubiquitin proteasome system in lung cancer progression. Cellular Oncology (Dordrecht), 0, , . | 4.4 | 0 |
| 154 | Histopathological analysis of tumor microenvironment in adrenocortical carcinoma: Possible effects of in situ disorganized glucocorticoid production on tumor immunity. Journal of Steroid Biochemistry and Molecular Biology, 2024, 238, 106462. | 2.5 | 0 |
| 155 | The Application of Immunotherapy in Non-Small Cell Lung Cancer. Advances in Clinical Medicine, 2024, 14, 921-925. | 0.0 | 0 |
| 156 | Long non-coding RNA CCAT1 acts as an oncogene to promote radiation resistance in lung adenocarcinoma: an epigenomics-based investigation. Functional and Integrative Genomics, 2024, 24, . | 3.5 | 0 |